TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Southpoint holdings in Fennec Pharmaceuticals Inc. (TSX: FENC)

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Na
Southpoint holdings in Fennec Pharmaceuticals Inc. (TSX: FENC)

Southpoint Capital Advisors sold 1 million common shares (2.93%) of Fennec Pharmaceuticals on December 24, 2025, at USD $7.50 per share. The firm retains control of 2.7 million shares (approximately 8% of outstanding shares on a fully diluted basis) and may adjust its position based on market conditions.

Insights
BACpL   neutral

Buffett trimmed the position by 26.3 million shares, suggesting a measured approach to the financial sector


FENC   neutral

The sale itself is a neutral event as it reflects a portfolio rebalancing by a major shareholder rather than a negative assessment of the company. Southpoint's retention of 8% ownership and the stated investment purpose indicate continued confidence in Fennec's prospects.